HG202

GENETIC2 trials

Sponsors

HuidaGene Therapeutics Co., Ltd.

Conditions

Neovascular Age-Related Macular Degeneration (nAMD)Neovascular Age-related Macular Degeneration(nAMD)

Early Phase 1

CRISPR/cas13-medIated RNA TarGeting THerapy for the Treatment of Neovascular Age-related Macular Degeneration Investigator-initiated Trial (SIGHT-I)

RecruitingNCT06031727

HuidaGene Therapeutics Co., Ltd.Neovascular Age-related Macular Degeneration(nAMD)

Start: 2023-09-04End: 2026-06-30Target: 12Updated: 2025-03-17

Phase 1

Open-laBel Dose-escalation Study for CRISPR/cas13- Rna TargetInG THerapy for the Treatment of Neovascular Age-related Macular Degeneration in Phase I Trial

Not yet recruitingNCT06623279

HuidaGene Therapeutics Co., Ltd.Neovascular Age-Related Macular Degeneration (nAMD)

Start: 2025-04-01End: 2031-02-01Target: 15Updated: 2024-10-02